This document contains a table of core profit and loss forecasts for GlaxoSmithKline from FY14A to FY20E, including sales, growth, pharmaceuticals, consumer health, cost of sales, gross profit, SG&A, R&D, royalty income, operating profit, net interest, JVs & associates, profit before tax, tax expense, profit after tax, minority share, shareholders' share, core EPS, and ordinary dividend per share.
documents/vol00010-efta01457563-pdf.pdf
{"title":"Core P&L forecasts for GlaxoSmithKline","document_date":"2015-05-11","document_type":"tabular","key_locations":["London"],"key_organizations":["GlaxoSmithKline","Deutsche Bank AG"]}